Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency
Geoff Charles‐Edwards, Nelson Amaral, Alison Sleigh, et al.
Circulation (2019) Vol. 139, Iss. 21, pp. 2386-2398
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Piotr Ponikowski, Stefan D. Anker, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1169-1186
Open Access | Times Cited: 580
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, et al.
The Lancet (2022) Vol. 400, Iss. 10369, pp. 2199-2209
Open Access | Times Cited: 256
Iron deficiency without anaemia: a diagnosis that matters
Abdulrahman Al-Naseem, Abdelrahman Sallam, Shamim Choudhury, et al.
Clinical Medicine (2021) Vol. 21, Iss. 2, pp. 107-113
Open Access | Times Cited: 122
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 103
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis
Piotr Ponikowski, Robert J. Mentz, Adrian F. Hernandez, et al.
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5077-5091
Open Access | Times Cited: 84
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial
Stephan von Haehling, Wolfram Doehner, Ruben Evertz, et al.
European Heart Journal (2024) Vol. 45, Iss. 37, pp. 3789-3800
Open Access | Times Cited: 21
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper
Loreena Hill, Tal Prager Geller, Resham Baruah, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 12, pp. 2327-2339
Open Access | Times Cited: 134
Muscle wasting as an independent predictor of survival in patients with chronic heart failure
Stephan von Haehling, Tania Garfias Macedo, Miroslava Valentová, et al.
Journal of Cachexia Sarcopenia and Muscle (2020) Vol. 11, Iss. 5, pp. 1242-1249
Open Access | Times Cited: 105
Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology
Ridha I.S. Alnuwaysir, Martijn F. Hoes, Dirk J. van Veldhuisen, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 125-125
Open Access | Times Cited: 104
Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
Sunil Bhandari, Philip A. Kalra, Mario Berkowitz, et al.
Nephrology Dialysis Transplantation (2020) Vol. 36, Iss. 1, pp. 111-120
Open Access | Times Cited: 87
Risk of Infection Associated With Administration of Intravenous Iron
Akshay Shah, Killian Donovan, Claire Seeley, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2133935-e2133935
Open Access | Times Cited: 82
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial
Pieter Martens, Matthias Dupont, Jeroen Dauw, et al.
European Heart Journal (2021) Vol. 42, Iss. 48, pp. 4905-4914
Open Access | Times Cited: 80
Intravenous iron: a framework for changing the management of iron deficiency
Michael Auerbach, Anat Gafter‐Gvili, Iain C. Macdougall
The Lancet Haematology (2020) Vol. 7, Iss. 4, pp. e342-e350
Closed Access | Times Cited: 78
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety
Irina Blumenstein, Satish Shanbhag, Peter Langguth, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 7, pp. 757-769
Open Access | Times Cited: 63
Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?
Nils Bömer, Mario Pávez, Niels Grote Beverborg, et al.
Journal of Internal Medicine (2022) Vol. 291, Iss. 6, pp. 713-731
Open Access | Times Cited: 44
Iron deficiency and supplementation in heart failure
Samira Lakhal‐Littleton, John G.F. Cleland
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 463-486
Closed Access | Times Cited: 13
Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials
Fraser J Graham, Pierpaolo Pellicori, Ian Ford, et al.
Clinical Research in Cardiology (2021) Vol. 110, Iss. 8, pp. 1299-1307
Open Access | Times Cited: 44
Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans
Hao Zhang, K. Lockhart Jamieson, Justin Grenier, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 35
Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis
Davor Vukadinović, Amr Abdin, Insa E. Emrich, et al.
Clinical Research in Cardiology (2023) Vol. 112, Iss. 7, pp. 954-966
Open Access | Times Cited: 22
Iron deficiency is related to lower muscle mass in community‐dwelling individuals and impairs myoblast proliferation
Joanna Sophia J. Vinke, Alan Gorter, Michele F. Eisenga, et al.
Journal of Cachexia Sarcopenia and Muscle (2023) Vol. 14, Iss. 4, pp. 1865-1879
Open Access | Times Cited: 19
Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications
Pieter Martens, Shilin Yu, Brett Larive, et al.
European Heart Journal (2023) Vol. 44, Iss. 22, pp. 1979-1991
Open Access | Times Cited: 17
Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 6, pp. 1298-1312
Open Access | Times Cited: 7
Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure
Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 12, pp. 1651-1658
Open Access | Times Cited: 48
Cardiac iron concentration in relation to systemic iron status and disease severity in non‐ischaemic heart failure with reduced ejection fraction
Valentin G. Hirsch, Jörn Tongers, Julia Bode, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 11, pp. 2038-2046
Open Access | Times Cited: 43
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design
Robert J. Mentz, Andrew P. Ambrosy, Justin A. Ezekowitz, et al.
Circulation Heart Failure (2021) Vol. 14, Iss. 5
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top